Following a two-day oral hearing before the Boards of Appeal in T0295/22-3.3.07, the European Patent EP 2962690 (active ingredient: Apremilast) has been fully revoked. This decision also invalidates the supplementary protection certificates based on the patent.
Our partner Wolfgang Sandmann is proud to have contributed to this significant success alongside a strong team of opponents. The revocation highlights the importance of a thorough and well-executed patent strategy.
A vital victory for fair competition and the integrity of the European patent system!